Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 7/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20031922 | 0.76 | AKR1C3 (0.41) | AKR1C3AKR1C2SCN9AARKMO | |
| SCHEMBL8322023 | 0.75 | PTPN5 (0.42) | AKR1C3AKR1C2NOTUM | |
| SCHEMBL9649088 | 0.74 | LMNA (0.33) | AKR1C3AKR1C2 | |
| SCHEMBL3017106 | 0.73 | KMO (0.37) | AKR1C3AKR1C2SCN9AARKMO | |
| SCHEMBL7257158 | 0.72 | NOTUM (0.34) | ARNOTUMPDE2A | |
| SCHEMBL8319067 | 0.71 | GCGR (0.33) | — | |
| SCHEMBL694761 | 0.70 | RAPGEF4 (0.43) | SCN9AARNOTUM | |
| SCHEMBL6170221 | 0.69 | NOTUM (0.34) | ARNOTUMPDE2A | |
| SCHEMBL9967733 | 0.69 | PDE2A (0.43) | AKR1C3AKR1C2KMOTRPV3NOTUM | |
| SCHEMBL4764016 | 0.69 | AR (0.43) | SCN9AARKMONOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | claimed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | claimed |
| US-8653262-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | CCR2, CCRL2, CCR1 | AKR1C3 356/4885AKR1C2 547/4885SCN9A 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.